Accumulating evidence from large-scale clinical trials demonstrates that NSCLC patients with ALK rearrangements achieve significant survival benefits from ALK-TKI therapy compared to chemotherapy (Wu et al., 2024; Novello et al., 2018). Here, ALK is linked to non-small cell lung carcinoma.